XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Advanced breast cancer
Everolimus
Exemestane
HR+/HER2−
Insulin-like growth factor
Non-visceral disease
Xentuzumab
Journal
Breast cancer research : BCR
ISSN: 1465-542X
Titre abrégé: Breast Cancer Res
Pays: England
ID NLM: 100927353
Informations de publication
Date de publication:
12 06 2023
12 06 2023
Historique:
received:
04
01
2023
accepted:
20
04
2023
medline:
14
6
2023
pubmed:
13
6
2023
entrez:
12
6
2023
Statut:
epublish
Résumé
Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by everolimus. This study evaluated the addition of xentuzumab to everolimus and exemestane in patients with advanced breast cancer with non-visceral disease. This double-blind, randomised, Phase II study was undertaken in female patients with hormone-receptor (HR)-positive/human epidermal growth factor 2 (HER2)-negative advanced breast cancer with non-visceral disease who had received prior endocrine therapy with or without CDK4/6 inhibitors. Patients received a weekly intravenous infusion of xentuzumab (1000 mg) or placebo in combination with everolimus (10 mg/day orally) and exemestane (25 mg/day orally). The primary endpoint was progression-free survival (PFS) per independent review. A total of 103 patients were randomised and 101 were treated (n = 50 in the xentuzumab arm and n = 51 in the placebo arm). The trial was unblinded early due to high rates of discordance between independent and investigator assessment of PFS. Per independent assessment, median PFS was 12.7 (95% CI 6.8-29.3) months with xentuzumab and 11.0 (7.7-19.5) months with placebo (hazard ratio 1.19; 95% CI 0.55-2.59; p = 0.6534). Per investigator assessment, median PFS was 7.4 (6.8-9.7) months with xentuzumab and 9.2 (5.6-14.4) months with placebo (hazard ratio 1.23; 95% CI 0.69-2.20; p = 0.4800). Tolerability was similar between the arms, with diarrhoea (33.3-56.0%), fatigue (33.3-44.0%) and headache (21.6-40.0%) being the most common treatment-emergent adverse events. The incidence of grade ≥ 3 hyperglycaemia was similar between the xentuzumab (2.0%) and placebo (5.9%) arms. While this study demonstrated that xentuzumab could be safely combined with everolimus and exemestane in patients with HR-positive/HER2-negative advanced breast cancer with non-visceral disease, there was no PFS benefit with the addition of xentuzumab. Trial registration ClinicalTrials.gov, NCT03659136. Prospectively registered, September 6, 2018.
Sections du résumé
BACKGROUND
Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by everolimus. This study evaluated the addition of xentuzumab to everolimus and exemestane in patients with advanced breast cancer with non-visceral disease.
METHODS
This double-blind, randomised, Phase II study was undertaken in female patients with hormone-receptor (HR)-positive/human epidermal growth factor 2 (HER2)-negative advanced breast cancer with non-visceral disease who had received prior endocrine therapy with or without CDK4/6 inhibitors. Patients received a weekly intravenous infusion of xentuzumab (1000 mg) or placebo in combination with everolimus (10 mg/day orally) and exemestane (25 mg/day orally). The primary endpoint was progression-free survival (PFS) per independent review.
RESULTS
A total of 103 patients were randomised and 101 were treated (n = 50 in the xentuzumab arm and n = 51 in the placebo arm). The trial was unblinded early due to high rates of discordance between independent and investigator assessment of PFS. Per independent assessment, median PFS was 12.7 (95% CI 6.8-29.3) months with xentuzumab and 11.0 (7.7-19.5) months with placebo (hazard ratio 1.19; 95% CI 0.55-2.59; p = 0.6534). Per investigator assessment, median PFS was 7.4 (6.8-9.7) months with xentuzumab and 9.2 (5.6-14.4) months with placebo (hazard ratio 1.23; 95% CI 0.69-2.20; p = 0.4800). Tolerability was similar between the arms, with diarrhoea (33.3-56.0%), fatigue (33.3-44.0%) and headache (21.6-40.0%) being the most common treatment-emergent adverse events. The incidence of grade ≥ 3 hyperglycaemia was similar between the xentuzumab (2.0%) and placebo (5.9%) arms.
CONCLUSIONS
While this study demonstrated that xentuzumab could be safely combined with everolimus and exemestane in patients with HR-positive/HER2-negative advanced breast cancer with non-visceral disease, there was no PFS benefit with the addition of xentuzumab. Trial registration ClinicalTrials.gov, NCT03659136. Prospectively registered, September 6, 2018.
Identifiants
pubmed: 37308971
doi: 10.1186/s13058-023-01649-w
pii: 10.1186/s13058-023-01649-w
pmc: PMC10258741
doi:
Substances chimiques
exemestane
NY22HMQ4BX
Everolimus
9HW64Q8G6G
xentuzumab
X86Z1O656G
Androstadienes
0
Banques de données
ClinicalTrials.gov
['NCT03659136']
Types de publication
Randomized Controlled Trial
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
67Informations de copyright
© 2023. The Author(s).
Références
Ann Oncol. 2021 Dec;32(12):1475-1495
pubmed: 34678411
Ann Oncol. 2015 Mar;26(3):497-504
pubmed: 25395283
Genes Dis. 2022 Mar 23;10(1):199-211
pubmed: 37013053
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Breast Cancer Res. 2021 Jan 29;23(1):14
pubmed: 33514405
Oncologist. 2021 Feb;26(2):101-106
pubmed: 33230905
J Clin Oncol. 2022 Oct 1;40(28):3246-3256
pubmed: 35584336
Mol Cancer Ther. 2014 Feb;13(2):399-409
pubmed: 24296829
Clin Cancer Res. 2019 Jun 15;25(12):3479-3485
pubmed: 30745299
Lancet Oncol. 2015 Apr;16(4):426-35
pubmed: 25795408
Ann Oncol. 2015 May;26(5):921-927
pubmed: 25609246
Target Oncol. 2017 Oct;12(5):571-597
pubmed: 28815409
Breast Cancer Res Treat. 2017 Oct;165(3):601-609
pubmed: 28681171
J Clin Oncol. 2004 Jul 15;22(14):2942-53
pubmed: 15254062
Br J Cancer. 2021 Apr;124(9):1581-1591
pubmed: 33723394
Int J Mol Sci. 2021 Jan 08;22(2):
pubmed: 33429867
Clin Breast Cancer. 2022 Feb;22(2):143-148
pubmed: 34740541
J Support Oncol. 2011 Mar-Apr;9(2):72-8
pubmed: 21542414
Life (Basel). 2022 Nov 29;12(12):
pubmed: 36556357
Br J Cancer. 2020 Apr;122(9):1324-1332
pubmed: 32161368
Neoplasia. 2015 Mar;17(3):279-88
pubmed: 25810012
J Natl Cancer Inst. 2012 Jul 3;104(13):975-81
pubmed: 22761272
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Clin Cancer Res. 2015 Jan 1;21(1):49-59
pubmed: 25320355
Breast Cancer Res. 2021 Jan 15;23(1):8
pubmed: 33451345
Clin Cancer Res. 2022 Aug 2;28(15):3256-3267
pubmed: 35583555
Clin Cancer Res. 2016 Jan 15;22(2):301-9
pubmed: 26324738
J Natl Compr Canc Netw. 2019 Feb;17(2):141-147
pubmed: 30787127